

ABOUT TIGENIX

Advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions.

Lead product, Cx601, obtained a positive CHMP opinion for the treatment of complex perianal fistula in Crohn's patients in Dec. 2017. Partnered ex-US with Takeda Pharmaceuticals. Global phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017.

Strong pipeline in inflammatory and autoimmune diseases.

QUICK FACTS

Website: www.tigenix.com
Ticker symbol: TIG (Euronext & NASDAQ)
Headquarters: Leuven, Belgium
Number of employees: > 100

UPCOMING MILESTONES

- EC ratification of positive CHMP opinion for Cx601
- Start patient enrollment in global phase III trial in North America
- Start development of new indications for Cx601

MANAGEMENT

- CEO: **Eduardo Bravo**
- CFO: **Dr. Claudia D'Augusta**
- CTO: **Dr. Wilfried Dalemans**
- CMO: **Dr. Marie Paule Richard**
- VP Regulatory Affairs and Corporate Quality: **Dr. Maria Pascual**
- VP Medical Affairs and Commercialization: **Dr. Mary Carmen Diez**
- Director of Human Resources: **Susana Rojo**

TECHNOLOGY AND PIPELINE

Two proprietary platforms of expanded allogeneic stem cells:

- Expanded adipose-derived stem cells (eASCs)
- Cardiac stem cells (CSCs)

Product candidates:

- **Cx601:** locally administered eASCs for the treatment of complex perianal fistulas in Crohn's disease patients. Partnered ex-US with Takeda Pharmaceuticals.

- **Cx611: Systemic (IV) administration** of eASCs for the treatment of **autoimmune diseases**. Cx611 is currently being evaluated in a **Phase I/II trial in severe sepsis** (the SEPCELL study).
- **AlloCSC-01: Intracoronary administration** of CSCs for the treatment of acute ischemic heart disease. 1 year data from **CAREMI Phase I/II study** demonstrated **safety in acute myocardial infarction (AMI)** and reduction in infarct size in a subset of patients with a large MI and poor prognosis.

	Product	Indication	Preclinic	Phase I	Phase II	Phase III	Registration / Market
Allogeneic Adipose-Derived Stem Cells	Cx601 (EU)	Complex Perianal Fistulas in Crohn's disease*	Partnered; Positive CHMP opinion received Dec. 2017				
	Cx601 (USA)	Complex Perianal Fistulas in Crohn's disease	Global Phase III for BLA started 1H2017				
	Cx611 (intravenous)	Severe Sepsis					
Allogeneic Cardiac Stem Cells	AlloCSC-01 (intracoronary)	Acute Myocardial Infarction					